In January GEROPHARM registered Levetinol® in a new form – Levetinol®, oral solution, 100 mg/ml. The drug used to be in the form of film-coated tablets in the strength of 250 mg, 500 mg and 1,000 mg. The solution is expected to be launched into commercial circulation in the third quarter of 2017.
This form is preferred since it is more convenient for administration, especially for children. Apart from that, the active substance in the form of solution has a more rapid effect.
Development of this drug was based on the original medicinal product Keppra® (INN: levetiracetam) oral solution, 100 mg/ml (manufactured by NextPharma S. a. S., France).